FrancophonIA/ELRC3.0 huggingface dataset:
English: The most common side effects with NeuroBloc (which may affect more than 1 in 10 people) are dry mouth, headache (in patients new to treatment with botulinum toxins), dysphagia (difficulty swallowing) and pain at the site of the injection.
Croatian: Najčešće nuspojave povezane s liječenjem lijekom NeuroBloc (koje se mogu javiti u više od 1 na 10 osoba) jesu suha usta, glavobolja (u bolesnika koji se prvi put liječe botulinskim toksinima), disfagija (otežano gutanje) i bol na mjestu primjene injekcije.
English: NeuroBloc must not be used in patients with other neuromuscular (nerve and muscle) disorders.
Croatian: Lijek NeuroBloc ne smije se primjenjivati u bolesnika s drugim neuromuskularnim bolestima (koje zahvaćaju živce i mišiće).
English: When injected directly into a muscle it reduces the release of acetylcholine and muscle contraction in the affected neck or shoulder muscles, thereby relieving the patient's symptoms.
Croatian: Kada se ubrizgava izravno u mišić, smanjuje otpuštanje acetilkolina i stezanje mišića u zahvaćenim mišićima glave i ramena, čime se olakšavaju simptomi bolesnika.
English: In NeuroBloc, the toxin is used as a muscle relaxant.
Croatian: U lijeku NeuroBloc toksin se upotrebljava kao mišićni relaksans.
English: Acetylcholine is needed to transfer electrical impulses from the nerves to the muscles in order for the muscles to contract.
Croatian: Acetilkolin je potreban za prijenos električnih impulsa iz živaca u mišiće kako bi se stezali.
English: What are the risks associated with NeuroBloc?
Croatian: Koji su rizici povezani s lijekom NeuroBloc?
English: As for all medicines, data on the use of NeuroBloc are continuously monitored.
Croatian: Kao za sve lijekove, podaci o primjeni lijeka NeuroBloc kontinuirano se prate.
English: An overview of NeuroBloc and why it is authorised in the EU
Croatian: Pregled informacija o lijeku NeuroBloc i zašto je odobren u EU-u
English: The European Medicines Agency decided that NeuroBloc's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi lijeka NeuroBloc nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: NeuroBloc is a medicine used to treat cervical dystonia in adults.
Croatian: NeuroBloc je lijek indiciran za liječenje cervikalne distonije u odraslih.
English: The active substance in NeuroBloc, botulinum toxin type B, is a well-known toxic substance produced by the bacterium Clostridium botulinum.
Croatian: Djelatna tvar u lijeku NeuroBloc, botulinski toksin tipa B, dobro je poznata toksična tvar proizvedena u stanicama bakterije Clostridium botulinum.
English: NeuroBloc (botulinum toxin type B)
Croatian: NeuroBloc (botulinski toksin tipa B)
English: The medicine improved the TWSTRS score of the non-responders to type A botulinum toxin as well as the score of the responders.
Croatian: Lijek je poboljšao rezultat na ljestvici TWSTRS kod bolesnika koji nisu reagirali na botulinski toksin tipa A, kao i rezultat bolesnika koji su reagirali.
English: How does NeuroBloc work?
Croatian: Kako djeluje NeuroBloc?
English: NeuroBloc contains the active substance botulinum toxin type B.
Croatian: NeuroBloc sadrži djelatni sastojak botulinski toksin tipa B.
English: What benefits of Neurobloc have been shown in studies?
Croatian: Koje su koristi od lijeka NeuroBloc utvrđene u ispitivanjima?
English: How is NeuroBloc used?
Croatian: Kako se NeuroBloc koristi?
English: For the full list of side effects reported with NeuroBloc, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka NeuroBloc, potražite u uputi o lijeku.
English: Three of the studies included patients who had stopped responding to type A botulinum toxin (another type of botulinum toxin that may also be used to treat cervical dystonia), and the fourth only included patients who did respond to type A toxin.
Croatian: A (drugi tip botulinskog toksina koji se također može koristiti za liječenje cervikalne distonije), dok je četvrto ispitivanje obuhvaćalo samo bolesnike koji su reagirali na botulinski toksin tipa A.
English: EMA/785026/2012
Croatian: EMA/167154/2015 EMEA/H/C/004006
English: This summary was last updated in 11-2012.
Croatian: Sažetak je posljednji put ažuriran u 02.2015.
English: The full EPAR for Clopidogrel ratiopharm can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR kao i plan upravljanja rizikom za lijek Clopidogrel rationpharm nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: • patients who have recently had a myocardial infarction (heart attack).
Croatian: • bolesnika koji su nedavno pretrpjeli infarkt miokarda (srčani zastoj).
English: The standard dose of Clopidogrel ratiopharm is one 75 mg tablet once a day.
Croatian: Preporučena je doza jedna tableta od 75 mg na dan.
English: This means that Clopidogrel ratiopharm is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Croatian: To znači da je Clopidogrel rationpharm sličan „referentnom lijeku” koji je već odobren u Europskoj uniji pod nazivom Plavix.
English: This is a summary of the European public assessment report (EPAR) for Clopidogrel ratiopharm.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Clopidogrel ratiopharm.
English: • patients with peripheral arterial disease (problems with blood flow in the arteries).
Croatian: • bolesnika s bolesti perifernih arterija (problemima s protokom krvi u arterijama);
English: Therefore, the CHMP's view was that, as for Plavix, the benefit outweighs the identified risk.
Croatian: Stoga je stav CHMP-a da, kao u slučaju lijeka Plavix, koristi nadmašuju utvrđeni rizik.
English: Clopidogrel ratiopharm can be started between a few days and 35 days after the attack;
Croatian: Terapija lijekom Clopidogrel rationpharm može se započeti od nekoliko dana do 35 dana nakon infarkta;
English: This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.
Croatian: Ovo sprječava "lijepljenje" trombocita", smanjujući rizik od formiranja krvnih ugrušaka i pomaže pri sprječavanju infarkta miokarda ili moždanog udara.
English: Because Clopidogrel ratiopharm is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.
Croatian: Budući da je Clopidogrel rationpharm generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegovi koristi i rizici isti kao i oni referentnog lijeka.
English: Clopidogrel ratiopharm can be started between seven days and six months after
Croatian: Terapija lijekom Clopidogrel rationpharm može se započeti od sedam dana do šest mjeseci nakon udara;
English: For more information about treatment with Clopidogrel ratiopharm, read the package leaflet (also part of the EPAR) or contact your
Croatian: Više informacija o terapiji lijekom Clopidogrel rationpharm pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Clopidogrel ratiopharm is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Croatian: Clopidogrel rationpharm je lijek za razrijeđivanje krvi koji se primjenjuje u odraslih bolesnika za sprječavanje aterotrombotičkih događaja (problema uzrokovanih krvnim ugrušcima i ukručivanje arterija).
English: Because Clopidogrel ratiopharm is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Croatian: Budući da je Clopidogrel rationpharm generički lijek, ispitivanja na bolesnicima bila su ograničena na ispitivanja za utvrđivanje da je lijek bioekvivalentan referentnom lijeku Plavix.
English: Clopidogrel ratiopharm is a ‘generic medicine'.
Croatian: Clopidogrel rationpharm je "generički lijek".
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel ratiopharm.
Croatian: Objašnjava kako je Agencija ocijenila lijek da bi preporučila njegovo odobrenje u EU-u te uvjete za njegovu primjenu.
English: What are the benefits and risks of Clopidogrel ratiopharm?
Croatian: Koje su koristi i rizici lijeka Clopidogrel rationpharm?
English: The active substance in Clopidogrel ratiopharm, clopidogrel, is an inhibitor of platelet aggregation.
Croatian: Djelatna tvar lijeka Clopidogrel rationpharm, klopidogrel, jest inhibitor nakupljanja trombcita.
English: The CHMP concluded that, in accordance with EU requirements, Clopidogrel ratiopharm has been shown to have comparable quality and to be bioequivalent to Plavix.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključio je kako je, u skladu sa zahtjevima EU-a, potvrđeno kako Clopidogrel rationpharm posjeduje usporedivu kakvoću te je bioekvivalentan s lijekom Plavix.
English: Clopidogrel ratiopharm can be given to the following groups
Croatian: Clopidogrel rationpharm može se primjenjivati u sljedećih grupa bolesnika:
English: Why has Clopidogrel ratiopharm been approved?
Croatian: Zašto je Clopidogrel rationpharm odobren?
English: Other information about Clopidogrel ratiopharm
Croatian: Ostale informacije o lijeku Clopidogrel rationpharm
English: The Committee recommended that Clopidogrel ratiopharm be given marketing authorisation.
Croatian: Odbor je preporučio odobrenje lijeka Clopidogrel rationpharm za korištenje u EU-u.
English: The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je na snazi u Europskoj uniji za Clopidogrel rationpharm od 19. veljače 2015.
English: Clopidogrel ratiopharm is a medicine that contains the active substance clopidogrel.
Croatian: Clopidogrel rationpharm sadrži djelatnu tvar klopidogrel.
English: What is Clopidogrel ratiopharm used for?
Croatian: Što je Clopidogrel rationpharm i za što se koristi?
English: How has Clopidogrel ratiopharm been studied?
Croatian: Kako je Clopidogrel rationpharm ispitivan?
English: How is Clopidogrel ratiopharm used?
Croatian: Kako se Clopidogrel rationpharm koristi?
English: Clopidogrel ratiopharm EMA/785026/2012
Croatian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555
English: The medicine can only be obtained with a prescription.
Croatian: Clopidogrel rationpharm izdaje se samo na liječnički recept.
English: This summary was last updated in May 2015.
Croatian: Sažetak je posljednji put ažuriran u svibnju 2015.
English: An occasional temporary, acute (short-term) hypersensitivity (allergic) reaction may occur.
Croatian: Ponekad može nastupiti privremena, akutna (kratkotrajna) reakcija preosjetljivosti (alergijska reakcija).
English: The company has presented data from both laboratory and field studies to establish the safety and effectiveness of the vaccine, including how long it took for the dogs to be fully protected and how long the vaccine could provide protection.
Croatian: Tvrtka je dostavila podatke iz laboratorijskih i terenskih ispitivanja kako bi se utvrdile sigurna primjena i djelotvornost cjepiva, uključujući razdoblje potrebno da bi se psi u potpunosti zaštitili i koliko je dugo cjepivo pružalo imunizaciju.
English: A mild and temporary increase in body temperature (1°C or less) may occur for a few days after vaccination, with some puppies showing less activity and/or a reduced appetite.
Croatian: Blago i privremeno povećanje tjelesne temperature (1°C ili manje) može nastupiti nekoliko dana nakon cijepljenja, pri čemu su pojedini štenci pokazali smanjenu aktivnost i/ili smanjeni apetit.
English: Canigen L4 contains four types of inactivated (killed) Leptospira strains: L. interrogans serogroup Canicola serovar Portland-vere, L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar Bratislava, L. kirschneri serogroup Grippotyphosa serovar Dadas.
Croatian: Canigen L4 sadrži četiri tipa inaktiviranih (ubijenih) sojeva bakterije Leptospira: L. interrogans serogrupa Canicola serovar Portland-vere, L. interrogans serogrupa Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogrupa Australis serovar Bratislava, L. kirschneri serogrupa Grippotyphosa serovar Dadas.
English: In the future, if the animals are exposed to these Leptospira bacteria the immune system will be able to respond more quickly.
Croatian: Ako životinje u budućnosti budu izložene tim bakterijama Leptospira, imunosni sustav moći će brže reagirati.
English: The bacteria are spread via the urine of infected animals.
Croatian: Bakterija se širi putem urina zaraženih životinja.
English: This vaccine is the same as Nobivac L4, which is already authorised in the European Union (EU).
Croatian: Ovo cjepivo isto je kao i Nobivac L4, koje je već odobreno u Europskoj uniji (EU).
English: They also showed that the vaccine is safe to give to pregnant bitches.
Croatian: Također je pokazalo da je cjepivo sigurno za primjenu u gravidnih kujica.
English: In dogs, leptospirosis can cause bleeding, hepatitis (inflammation of the liver) and jaundice (yellowing of the skin and eyes) or nephritis (kidney inflammation).
Croatian: Kod pasa leptospiroza može uzrokovati krvarenje, hepatitis (upalu jetre) i žuticu (žućenje kože i očiju) ili nefritis (upalu bubrega).
English: Protection starts three weeks after vaccination and lasts one year.
Croatian: Imunizacija nastupa tri tjedna nakon cijepljenja i traje godinu dana.
English: The strains of Leptospira bacteria in Canigen L4 are killed (inactivated) so that they do not cause disease.
Croatian: Sojevi bakterije Leptospira u cjepivu Canigen L4 ubijeni su (inaktivirani) tako da ne uzrokuju bolest.
English: Canigen L4 is a veterinary vaccine used to vaccinate dogs from six weeks of age to protect against leptospirosis caused by one of four specific types of Leptospira bacteria.
Croatian: Canigen L4 je veterinarsko cjepivo koje se koristi za cijepljenje pasa u dobi od šest tjedana i starijih za imunizaciju od leptospiroze uzrokovane jednim od četiri specifična tipa bakterije Leptospira.
English: Canine leptospirosis vaccine (inactivated)
Croatian: Cjepivo protiv pseće leptospiroze (inaktivirano)
English: A small, temporary swelling may occur at the injection site, which will either disappear or reduce in size within two weeks after vaccination.
Croatian: Na mjestu injekcije može nastupiti mali privremeni otok, koji će zatim nestati ili će se smanjiti unutar dva tjedna nakon cijepljenja.
English: Canigen L4 is available as a suspension for injection and can only be obtained with a prescription.
Croatian: Canigen L4 dostupan je kao suspenzija za injekciju i izdaje se samo na recept.
English: When Canigen L4 is given to dogs the animals' immune system recognises the bacteria as ‘foreign' and makes defences against them.
Croatian: Kada se Canigen L4 daje psima, imunosni sustav životinje prepoznaje bakterije kao „strana tijela” i proizvodi protutijela na njih.
English: The studies showed that the vaccine reduces infection with Leptospira and excretion of the bacteria into the urine.
Croatian: Ta su ispitivanja pokazala da cjepivo smanjuje infekciju bakterijom Leptospira i ekskreciju bakterije u urin.
English: The company that makes Nobivac L4 has agreed that its scientific data can be used for Canigen L4 (‘informed consent').
Croatian: Proizvođač cjepiva Nobivac L4 pristao je da se njegovi znanstveni podaci koriste za Canigen L4 (tzv. „informirani pristanak”).
English: The vaccine is given to dogs as two injections, four weeks apart, under the skin.
Croatian: Cjepivo se primjenjuje u pasa kao dvije potkožne injekcije, u razmaku od četiri tjedna.
English: A single ‘booster' injection should be given every year to maintain the vaccine's effect.
Croatian: Kako bi se održalo djelovanje cjepiva, svake godine treba primijeniti jednu dopunsku („booster”) injekciju.
English: For some strains of Leptospira, the vaccine also reduces the excretion (shedding) of the bacteria into the urine by the infected dogs, thereby reducing the risk of transmission.
Croatian: U slučaju pojedinih sojeva bakterije Leptospira, cjepivo također smanjuje ekskreciju (izlučivanje) bakterije u urin zaraženih pasa, te tako smanjuje rizik od prijenosa.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Canigen L4's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za veterinarsko-medicinske proizvode (CVMP) pri Agenciji odlučio je da koristi od VMP-a Canigen L4 nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za primjenu u Europskoj uniji.
English: This will help protect them against leptospirosis.
Croatian: To pomaže pri njihovoj zaštiti od bolesti.
English: The European Commission granted a marketing authorisation valid throughout the EU for Canigen L4 on 3 July 2015.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za VMP Canigen L4 na snazi u Europskoj uniji od 3.7.2015.
English: Canigen L4 is a vaccine.
Croatian: Canigen L4 je cjepivo.
English: This is a summary of the European public assessment report (EPAR) for Canigen L4.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za veterinarsko-medicinski proizvod Canigen L4.
English: What is Canigen L4 and what is it used for?
Croatian: Što je Canigen L4 i za što se koristi?
English: It is not intended to provide practical advice on how to use Canigen L4.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni VMP-a Canigen L4.
English: For practical information about using Canigen L4, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Croatian: Praktične informacije o primjeni VMP-a Canigen L4 vlasnici životinja ili uzgajivači trebaju pročitati u uputi o VMP-u, odnosno trebaju se obratiti svojem veterinaru ili ljekarniku.
English: What are the risks associated with Canigen L4?
Croatian: Koji su rizici povezani s VMP-om Canigen L4?
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom high levels of maternally derived antibodies (special type of proteins, received from the mother in the milk, that help the body to fight infection), it is recommended that the first vaccination is given at nine weeks of age.
Croatian: Kada je poznato da štenci imaju visoke koncentracije protutijela dobivenih od majke (posebnog tipa proteina primljenih iz majčinog mlijeka koji pomažu tijelu da se bori protiv infekcija), preporuča se primjena prvog cjepiva u dobi od devet tjedana.
English: Other information about Canigen L4
Croatian: Ostale informacije o VMP-u Canigen L4
English: Why is Canigen L4 approved?
Croatian: Zašto je VMP Canigen L4 odobren?
English: The full EPAR for Canigen L4 can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za VMP Canigen L4 nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Dodatne informacije o terapiji VMPom Canigen L4 vlasnici životinja ili uzgajivači trebaju pročitati u uputi o VMP-u, odnosno trebaju se obratiti svojem veterinaru ili ljekarniku.
English: How is Canigen L4 used?
Croatian: Kako se Canigen L4 koristi?
English: What benefits of Canigen L4 have been shown in studies?
Croatian: Koje su koristi VMP-a Canigen L4 utvrđene u ispitivanjima?
English: How does Canigen L4 work?
Croatian: Kako djeluje Canigen L4?
English: What is Otezla and what is it used for?
Croatian: Što je Otezla i za što se koristi?
English: The medicine is available as tablets (10, 20 and 30 mg).
Croatian: Lijek je dostupan kao tablete (10, 20 i 30 mg).
English: The full EPAR and risk management plan summary for Otezla can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Otezla nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Treatment is started with a dose of 10 mg on day 1 and gradually increased over a week to the recommended dose of 30 mg twice a day.
Croatian: Terapiju treba započeti s dozom od 10 mg prvog dana i postupno je povećavati tijekom tjedan dana do preporučene doze od 30 mg dva puta na dan.
English: Response to treatment should be evaluated regularly and use of Otezla should be reconsidered if there is no improvement after six months.
Croatian: Odgovor na terapiju treba redovito ocjenjivati, a primjenu lijeka Otezla treba razmotriti ako nema poboljšanja nakon šest mjeseci.
English: Patients who were already taking other so-called ‘small-molecule DMARDs' such as the medicine methotrexate continued this treatment during the study.
Croatian: Bolesnici koji su već uzimali druge takozvane „male molekule DMARD-ova“ poput lijeka metotreksata nastavili su s ovim liječenjem tijekom ispitivanja.
English: Lower doses should be given to patients with severe impairment of kidney function.
Croatian: Manje doze treba davati bolesnicima s teškim oštećenjem funkcije bubrega.
English: What measures are being taken to ensure the safe and effective use of Otezla?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Otezla?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Otezla on 15 January 2015.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Otezla na snazi u Europskoj uniji od 15. siječnja 2015.
English: The main measure of effectiveness in both studies was the proportion of patients who ‘responded' to treatment after 16 weeks.
Croatian: Glavna mjera djelotvornosti u oba ispitivanja bio je omjer bolesnika koji su „odgovorili“ na liječenje nakon 16 tjedana.
English: It is not intended to provide practical advice on how to use Otezla.
Croatian: Svrha sažetka nije davati praktične savjete o korištenju lijeka Otezla.
English: Why is Otezla approved?
Croatian: Zašto je lijek Otezla odobren?
English: Otezla must not be used during pregnancy, and women who can become pregnant should use an effective means of contraception during treatment.
Croatian: Otezla se ne smije primjenjivati tijekom trudnoće, a žene reproduktivne dobi trebaju koristiti djelotvorna sredstva kontracepcije tijekom terapije.
English: These usually occur within the first two weeks of treatment, and get better within 4 weeks.
Croatian: Isti se najčešće javljaju unutar prva dva tjedna nakon terapije te se poboljšavaju unutar 4 tjedna.
English: The Committee therefore considered that it was useful as a second-line treatment in patients who do not respond to or cannot use the first-line treatments.
Croatian: Stoga je odbor zaključio da je ovaj lijek koristan kao terapija druge linije u bolesnika koji nisu odgovorili na ili ne mogu koristiti terapije prve linije.
English: This was achieved in between 32 and 41% of patients given the approved dose of Otezla in the three studies, compared with 18 to 19% of those given placebo.
Croatian: Ovo je postignuto u 32 i 41% bolesnika koji su primili odobrenu dozu lijeka Otezla u tri ispitivanja, u usporedbi s 18 do 19% onih koji su primili placebo.
English: The main measure of effectiveness was a 20% improvement in a score measuring symptoms such as tender and swollen joints (ACR-20) after 16 weeks of treatment.
Croatian: Glavna mjera djelotvornosti bilo je 20%-tno poboljšanje u odgovoru kojim se mjere simptomi poput osjetljivih i nateknutih zglobova (ACR-20) nakon 16 tjedana terapije.
English: What are the risks associated with Otezla?
Croatian: Koji su rizici povezani s lijekom Otezla?